Clinical trial
Efficacy, Safety and Tolerability of PrasugrEl 5mg or TIcagrelor 60mg in COmplex and Higher-Risk Indicated PCI/PatieNts: The Prospective, Randomized, Open-labeled, Blinded Endpoint (PROBE), Multi-center E5TION Trial
NCT04734353 is registered in ClinicalTrials.gov with Gyeongsang National University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy, Safety and Tolerability of PrasugrEl 5mg or TIcagrelor 60mg in COmplex and Higher-Risk Indicated PCI/PatieNts: The Prospective, Randomized, Open-labeled, Blinded Endpoint (PROBE), Multi-center E5TION Trial
- Lead sponsor
- Gyeongsang National University Hospital
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- January 15, 2020
- Completion date
- June 15, 2022
- Enrollment
- 492 (estimated)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.